The R&D-based pharmaceutical industry body Medicines Australia has commenced a review of its Code of Conduct and is inviting public submissions, the closing date for which is October 10.
"Health care professionals, consumers, government and industry all need to remain confident that the conduct of the industry, the provisions of the Code and its administration remain appropriate and relevant to their interests," according to Ian Chalmers, chief executive of Medicines Australia.
Code already "world leading"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze